A possible contributor to erythropoiesis-stimulating agents requirement in hemodialysis: Paraoxonase 1 activity
Open Access
- 29 July 2021
- journal article
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 3 (3), 116-122
- https://doi.org/10.46310/tjim.882813
Abstract
Background: Anemia is one of the most prevalent complications of chronic kidney disease (CKD). In CKD-related anemia, circulating erythrocytes have a decreased life span. Paraoxonase-1 (PON1) activity is one of the essential factors protecting cell membranes, e.g., erythrocytes, from lipid peroxidation under normal conditions. In this study, we investigated PON1 activity in hemodialysis (HD) patients with and without erythropoiesis-stimulating agents (ESA) therapy and the possible relationship of PON1 activity levels with the ESA dose required. Methods: This study is composed of patients undergoing HD with a minimum dialysis vintage of six months. We excluded cases with an active infection, cardiovascular events and malignancy, hypo- or hyperthyroidism, central venous catheters, iron deficiency, cystic kidney diseases, nephrectomy, and routine C-reactive protein (CRP) levels higher than reference range within the last six months. Results: Baseline characteristics, laboratory parameters, oxidative stress, and systemic inflammatory indices were similar between groups. The mean PON1 activity of the ESA+ group was significantly lower than the ESA– group (191.4 ±118.8 and 488.1±174.9,respectively; pKeywords
This publication has 26 references indexed in Scilit:
- Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidationIUBMB Life, 2011
- Red Blood Cell Survival in Long-term Dialysis PatientsAmerican Journal of Kidney Diseases, 2011
- Protecting effect of vitamin E supplementation on submaximal exercise-induced oxidative stress in sedentary dogs as assessed by erythrocyte membrane fluidity and paraoxonase-1 activityThe Veterinary Journal, 2009
- Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortalityKidney International, 2008
- Uremic Toxins: What Are They? An Integrated Overview of Pathobiology and ClassificationJournal of Renal Nutrition, 2008
- Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholineAtherosclerosis, 2005
- Correlation Studies of Plasma Paraoxonase Activity and Uric Acid Concentration with AAPH‐Induced Erythrocyte Hemolysis in Hemodialysis PatientsArtificial Organs, 2004
- Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controlsEuropean Journal of Clinical Investigation, 2002
- Erythropoietin Response to Blood Loss in Hemodialysis Patients is Blunted but PreservedASAIO Journal, 1994
- Identification of a distinct human high‐density lipoprotein subspecies defined by a lipoprotein‐associated protein, K‐45JBIC Journal of Biological Inorganic Chemistry, 1993